Chrome Plugin Live! Redefine the way you read FinTwit 🚀 Install Now
Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on the developing gene therapies to cure blindness diseases. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, such as retinitis pigmentosa and leber congenital amaurosis; OCU410, gene therapy candidate for the treatment of dry age-related macular degeneration (AMD); and OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet AMD. Ocugen, Inc. has a strategic partnership with CanSino Biologics Inc. for gene therapy co-development and manufacturing; and Bharat Biotech for the commercialization of COVAXIN in the United States market. The company is headquartered in Malvern, Pennsylvania.
NASDAQ
Unprofitable
Unprofitable
210M
Biotechnology
Next Earning date - 13 May 2025
210M
Biotechnology
Next Earning date - 13 May 2025
Relative Strenght
18Volume Buzz
-26%Earning Acce
NoDist 52w H.
65%